b2b4cc41-5760-4463-bcde-16115ceb12c2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- DNA_REPAIR+0.400
- MYC_TARGETS_V2+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- FATTY_ACID_METABOLISM+0.300
- MYC_TARGETS_V1+0.300
- ADIPOGENESIS+0.200
- HEME_METABOLISM+0.200
- INTERFERON_ALPHA_RESPONSE+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- ALLOGRAFT_REJECTION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
- APICAL_SURFACE-0.200
- COMPLEMENT-0.200
- IL2_STAT5_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.861 |
| 2 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.860 |
| 3 | SRR10900021 | — | — | 0.854 |
| 4 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.844 |
| 5 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.843 |
| 6 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.838 |
| 7 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.833 |
| 8 | BSR_14_0066_A2_S94 | — | C | 0.831 |
| 9 | TCGA-A8-A09E-01A-11R-A00Z-07 | — | B | 0.830 |
| 10 | TCGA-BA-A6DL-01A-21R-A30B-07 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |